Please login to the form below

Not currently logged in
Email:
Password:

EMA drug communication reviewed

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report.

The report represents the outcome of a year-long project carried out by Dr Frederic Bouder, from Maatstricht University, on the invitation of the agency.

Dr Bouder carried out a detailed analysis of the expectations and attitudes of the agency's stakeholders towards its communication on medicines.

He recommended that the agency set up a risk communication advisory board, form a strategic view on transparency, involve patients in communication activities on a routine basis, and review the format and timing of its communication vehicles.

The EMA has started implementing some of Dr Bouder's suggestions. It is also considering his recommendations during the implementation of the new pharmacovigilance legislation.

The EMA has the report available to download (PDF).

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics